670 related articles for article (PubMed ID: 25459395)
1. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
4. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald V; Litière S; Young R; Messiou C; Lia M; Wardelmann E; van der Graaf W; Gronchi A; Judson I;
Eur J Cancer; 2016 Sep; 64():44-51. PubMed ID: 27323349
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.
Kasper B; Ouali M; van Glabbeke M; Blay JY; Bramwell VH; Woll PJ; Hohenberger P; Schöffski P
Eur J Cancer; 2013 Jan; 49(2):449-56. PubMed ID: 22975215
[TBL] [Abstract][Full Text] [Related]
6. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity.
Vlenterie M; Litière S; Rizzo E; Marréaud S; Judson I; Gelderblom H; Le Cesne A; Wardelmann E; Messiou C; Gronchi A; van der Graaf WT
Eur J Cancer; 2016 May; 58():62-72. PubMed ID: 26968015
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Young RJ; Litière S; Lia M; Hogendoorn PCW; Fisher C; Mechtersheimer G; Daugaard S; Sciot R; Collin F; Messiou C; Grünwald V; Gronchi A; van der Graaf W; Wardelmann E; Judson I
Acta Oncol; 2017 Jul; 56(7):1013-1020. PubMed ID: 28431480
[TBL] [Abstract][Full Text] [Related]
8. Current trials and new aspects in soft tissue sarcoma of adults.
Issels RD; Schlemmer M
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
[TBL] [Abstract][Full Text] [Related]
9. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
Gelderblom H; Blay JY; Seddon BM; Leahy M; Ray-Coquard I; Sleijfer S; Kerst JM; Rutkowski P; Bauer S; Ouali M; Marreaud S; van der Straaten RJ; Guchelaar HJ; Weitman SD; Hogendoorn PC; Hohenberger P
Eur J Cancer; 2014 Jan; 50(2):388-96. PubMed ID: 24215845
[TBL] [Abstract][Full Text] [Related]
10. Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) - A systematic review and meta-analysis.
Zer A; Prince RM; Amir E; Abdul Razak AR
Cancer Treat Rev; 2018 Feb; 63():71-78. PubMed ID: 29253836
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Younger E; Litière S; Le Cesne A; Mir O; Gelderblom H; Italiano A; Marreaud S; Jones RL; Gronchi A; van der Graaf WTA
Oncologist; 2018 Oct; 23(10):1250-1259. PubMed ID: 29650688
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH
J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365
[TBL] [Abstract][Full Text] [Related]
13. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
[TBL] [Abstract][Full Text] [Related]
14. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study.
Kroep JR; Ouali M; Gelderblom H; Le Cesne A; Dekker TJA; Van Glabbeke M; Hogendoorn PCW; Hohenberger P
Ann Oncol; 2011 Jan; 22(1):207-214. PubMed ID: 20656792
[TBL] [Abstract][Full Text] [Related]
15. Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.
Ray-Coquard I; Rizzo E; Blay JY; Casali P; Judson I; Hansen AK; Lindner LH; Dei Tos AP; Gelderblom H; Marreaud S; Litière S; Rutkowski P; Hohenberger P; Gronchi A; van der Graaf WT
Gynecol Oncol; 2016 Jul; 142(1):95-101. PubMed ID: 27208537
[TBL] [Abstract][Full Text] [Related]
16. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Lindner LH; Litière S; Sleijfer S; Benson C; Italiano A; Kasper B; Messiou C; Gelderblom H; Wardelmann E; Le Cesne A; Blay JY; Marreaud S; Hindi N; Desar IME; Gronchi A; van der Graaf WTA
Int J Cancer; 2018 Jun; 142(12):2610-2620. PubMed ID: 29383713
[TBL] [Abstract][Full Text] [Related]
19. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
20. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
